Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study

BACKGROUND: Anlotinib is used as a third-line treatment for advanced non-small-cell lung cancer (NSCLC), but has limited clinical benefits and several side effects, such as diarrhea and acneiform skin rash. Traditional Chinese Medicine (TCM) is commonly used to treat cancers in China. Chinese herbal...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wenmin, Lin, Jietao, Yang, Ting, xin Zhang, Ze, Tao, Lanting, Xiao, Zhiwei, Chen, Hanrui, Qi, Xiangjun, Sun, Lingling, Cao, Yang, Lin, Lizhu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893062/
https://www.ncbi.nlm.nih.gov/pubmed/36710490
http://dx.doi.org/10.1177/15347354221151147

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9893062/
https://www.ncbi.nlm.nih.gov/pubmed/36710490
http://dx.doi.org/10.1177/15347354221151147

Ejemplares similares